Market analysis, investment strategies, product updates, and everything you need to make better financial decisions.
The pharma giant scores 86/100 on reward with 251% net income growth. We analyse whether the pipeline justifies the …
CEO Erginbilgiç turned a "burning platform" into +94% returns in 12 months. We break down the 131.9% net income CAGR, a …
A rare 50% momentum stock or a value trap? We dig into NWG's massive cash pile and how it handles economic pressure.
Trading at 30x P/E; DCF models suggest 15-27% premium to intrinsic value
Read full analysis